Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness by Barrea, L. et al.
nutrients
Article
Impact of Nutritional Status on
Gastroenteropancreatic Neuroendocrine Tumors
(GEP-NET) Aggressiveness
Luigi Barrea 1,†,* , Barbara Altieri 1,2,† , Giovanna Muscogiuri 1, Daniela Laudisio 1 ,
Giuseppe Annunziata 3 , Annamaria Colao 1, Antongiulio Faggiano 1 and Silvia Savastano 1
1 Dipartimento di Medicina Clinica e Chirurgia, Unit of Endocrinology, Federico II University Medical School
of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy; altieri.barbara@gmail.com (B.A.);
giovanna.muscogiuri@gmail.com (G.M.); daniela.laudisio@libero.it (D.L.); colao@unina.it (A.C.);
afaggian@unina.it (A.F.); sisavast@unina.it (S.S.)
2 Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital,
University of Wuerzburg, 97080 Wuerzburg, Germany
3 Department of Pharmacy, University of Naples “Federico II”, Italy; Via Domenico Montesano, 49,
80131 Naples, Italy; giuseppe.annunziata@unina.it
* Correspondence: luigi.barrea@unina.it; Tel.: +39-081-746-3779
† These authors contributed equally to this work.
Received: 29 October 2018; Accepted: 22 November 2018; Published: 1 December 2018


Abstract: Neuroendocrine tumors (NETs) are rare neoplasms mostly originating from the
gastroenteropancreatic tract (GEP-NETs). Data regarding nutritional status in GEP-NET patients
are limited. The aim of the study was to investigate the nutritional status and adherence to the
Mediterranean Diet (MD) in GEP-NET patients and to correlate them with tumor aggressiveness.
A cross-sectional case-control observational study was conducted enrolling 83 patients with
well-differentiated G1/G2 GEP-NETs after resection, as well as 83 healthy subjects, age, sex
and body mass index-matched. Nutritional status was assessed by evaluating with Bioelectrical
Impedance analysis and its phase angle (PhA), adherence to the MD according to PREDIMED score,
dietary assessment, anthropometric parameters, and clinico-pathological characteristics. GEP-NET
patients consumed less frequently vegetables, fruits, wine, fish/seafood, nuts, and more frequently
red/processed meats, butter, cream, margarine, and soda drinks than controls. Patients with more
aggressive disease presented a lower adherence to MD according to PREDIMED categories in
comparison to G1, localized and free/stable disease status. A smaller PhA value and a lower
PREDIMED score were significantly correlated with G2 tumor, metastases, and progressive disease.
To the best of our knowledge, this is the first study reporting an association between nutritional status
and tumor aggressiveness in a selected group of GEP-NETs. Moreover, higher intakes of food of MD,
may represent a potential tool for prevention of tumor aggressiveness. Thus, a skilled nutritionist
should be an integral part of the multidisciplinary management of GEP-NET patients.
Keywords: gastroenteropancreatic neuroendocrine tumors; nutrition; tumor aggressiveness;
Mediterranean diet; bioelectrical impedance analysis
1. Introduction
Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~6.9
per 100,000. More than 50% of these tumors originate from the digestive system and are referred to as
gastroenteropancreatic NETs (GEP-NETs) [1]. The majority of GEP-NETs are diagnosed as incidental
findings or due to clinical manifestation related to tumor mass (non-functioning NETs) [2]. In about
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30% of cases, symptoms are related to hypersecretion of hormones and other biologically active
molecules (functioning NETs) which can induce different metabolic and gastrointestinal impairments,
such as hypoglycemia, hyperglycemia, peptic ulcers, diarrhea, steatorrhea, and altered gastrointestinal
motility [3]. Thus, tumor hypersecretion as well as the surgical approach in altering the anatomy of
the gastrointestinal tract, the somatostatin analogs treatment affecting the gut’s secretion, motility and
absorption, and systemic chemotherapy causing anorexia and weight loss, may all lead to an alteration
of the nutritional status in patients affected by GEP-NET [4].
Despite the nutritional status being largely affected in GEP-NET patients, only few studies
have investigated this topic. Recently, it was demonstrated that metabolic profile in patients
with non-functioning GEP-NET was associated with higher ki67% index and larger tumor size [5].
In contrast to this, a large analysis using the Nationwide Inpatient Sample showed that obesity could
represent a protective factor against inpatient mortality in abdominal NET patients [6]. The same
study also reported that malnutrition correlated with nearly 5-fold higher odds of inpatient mortality
in this group of patients [6]. It has been suggested that a poor nutritional status may negatively impact
the clinical outcome of patients with NET, extending the duration of hospitalization and reducing the
overall-survival [7,8]. Moreover, malnourished NET patients showed a worse response to transcatheter
arterial chemoembolization of liver metastases [9]. Maasberg et al. observed an association between
nutritional status and body composition evaluated through Bioelectrical Impedance Analysis (BIA)
and its derived parameter Phase Angle (PhA) in NET patients [8], as already reported in other cancer
types [10,11]. Particularly, the authors reported that malnutrition significantly correlated with poorer
BIA parameters and decreased PhA value [8]. No further details on nutritional status, dietary pattern,
and body composition in GEP-NET patients have been reported.
Evidence suggests that nutritional factors, such as the scarce adherence to the Mediterranean
diet (MD), could influence the aggressiveness of different tumor types, such as prostate, bladder, and
breast cancer [12–14], in addition to representing a dietary pattern suitable in both prevention and
mortality reduction of several cancer types [15]. Moreover, it has been reported that a low adherence
to the MD correlated with an increased risk of metabolic syndrome [16], that, as above mentioned, was
associated with larger and higher proliferative tumor in GEP-NET patients [5]. Recently, an association
between PhA measurements and adherence to the MD independently from confounding factors, such
as sex, age, and body weight in healthy subjects was observed [17]. Nowadays, nutritional guidelines
in GEP-NET patients are still missing and there is no evidence regarding the association between
the adherence to the MD and its potential association with tumor aggressiveness in patients with
GEP-NET. Thus, the evaluation of PhA value and the adherence to the MD could be particularly useful
to predict the nutritional status of GEP-NET patients.
The aim of this case-control, cross-sectional study was to investigate the nutritional status,
including adherence to the MD and dietary pattern, in a selected group of GEP-NET patients and to
evaluate the association of the nutritional status with different markers of tumor aggressiveness.
2. Materials and Methods
2.1. Design and Setting
This paper presnents a cross-sectional case-control observational study carried out at the
European Neuroendocrine Tumor Society (ENETS) Center of Excellence Multidisciplinary Group
for Neuroendocrine Tumors, Department of Clinical Medicine and Surgery, Unit of Endocrinology,
University “Federico II” of Naples. Both patients and controls were enrolled from January 2017 to July
2018. The work was conducted in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans, and approved by the Ethical Committee
of the University of Naples “Federico II” Medical School (n. 201/17). The protocol was explained
to both patients and controls, and a written informed consent was obtained. This cross-sectional
observational study was registered at clinicaltrials.gov with the number NCT03592940.
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2.2. Population Study
The study was conducted on 83 adult patients affected by GEP-NET out of 172 unselected
Caucasian patients with a diagnosis of NET attending the ENETS Centers of Excellence
Multidisciplinary Group for Neuroendocrine Tumors, University “Federico II”, Naples. To improve the
power of the study and the homogeneity of the investigated cohort, only patients with the following
criteria were included:
• Histological diagnosis of well-differentiated, low grade (G)1 and G2 GEP-NET, including sporadic
tumors or patients with multiple endocrine neoplasia type 1 (MEN1) syndrome, according to
classification of by the World Health Organization (WHO) [18];
• Non-functioning GEP-NET patients that were treatment-naïve (evaluated at the moment of the
diagnosis or before starting any medical treatment), or that discontinued Somatostatin Analogues
(SSAs) for more than 6 months or after endoscopic surgery performed more than 6 months before
the visit;
• Functioning GEP-NET patients who underwent endoscopic tumor resection and who were
biochemically free of disease for more than 6 months and who had not resumed medical treatment;
Patients with one or more of the following criteria were excluded from the study:
• Histological diagnosis of well-differentiated/high grade G3 GEP-NET or poorly-differentiated
neuroendocrine carcinomas (NEC) according to WHO classification [18], since it has been shown
that patients with G3 tumors were at risk of malnutrition [8];
• Diagnosis of bronchial or thymic NET, medullary thyroid cancer, Merkel cell carcinoma,
pheochromocytoma/paraganglioma;
• Ongoing medical treatment, including SSAs or targeted therapy, at the moment of the visit, since
they could affect the gastrointestinal secretory, motor, and absorptive functions or cause anorexia
and liver toxicity [5];
• Patients who had undergone major surgery, since it could change the anatomy of the
gastrointestinal tract;
• Patients with functioning GEP-NET that had been treated with curative surgery for less than
6 months before the visit;
• Patients with functioning GEP-NET that had not been treated at the moment of the visit, since the
secretion of hormones, peptides and amines could cause malabsorption, diarrhea, steatorrhea and
altered motility of the gastrointestinal tract [5];
• Patients on a hypocaloric diet in the last three months or specific nutritional regimens, including
vegan or vegetarian diets and vitamin/mineral or antioxidant supplementation;
• Presence of clinical conditions that could influence fluid balance and metabolism, including
diabetes mellitus, hypertension, liver or renal failure, acute or chronic inflammatory diseases,
history of cancer, based on a complete medical examination and laboratory investigations;
• Current administration of medicaments that could influence the fluid balance, including
non-steroidal anti-inflammatory drugs, hormone replacement therapy, diuretics or laxative;
• Abuse of alcohol defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM)-V
criteria [19];
Patients with pacemakers due to the potential interference with the device.
Eighty-three patients were enrolled together with healthy volunteers from the hospital and
employees from the same geographical area. Controls were matched by age, sex, and Body Mass
Index (BMI) and none had a history of cancer, diabetes mellitus, hypertension, liver or renal failure,
inflammatory disease, alcohol abuse and none of them consumed medicaments. To avoid the
overlapping enrollment, none of the controls contemporarily participated in other trials during the
period of this study. All the measurements were performed between 8 and 12 AM. All subjects were
measured after an overnight fast. The flow chart of the studied subjects is shown in Figure 1.
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rate, ki67 index, metastases, familiar history of MEN1, hormonal secretion, comorbidity, treatment 
and follow-up, were collected for all patients. 
Tumor size (mm) was defined as the maximum tumor diameter in the pathological specimen or 
in the last computed tomography (CT) scan/magnetic resonance imaging (MRI) when the patient 
had not undergone surgery or when the patient had multiple pancreatic nodules in case of MEN1. 
For these patients, the diameter of the biggest pancreatic lesion was considered for the tumor size. 
Only in a few cases (n = 3) was the tumor size not defined since the primary lesion had not been 
found. Tumor stage at diagnosis was classified according to the ENETS criteria [20]. According to 
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For the diagnosis of NET, immunohistochemistry for chromogranin A, synaptophysin and ki67 
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Figure 1. Flow chart of the studied subjects. A total of 83 patients affected by well differentiated
GEP-NET G1/G2 selected from 172 patients with NET attending the ENETS Centers of Excellence
Multidisciplinary Group for Neuroendocrine Tumors, University “Federico II”, Naples. Abbreviation:
NET, Neuroendocrine Tumor; GEP-NET, Gast oenteropancreatic NET; MTC, medullary thyr id cancer;
Pheo/PPG, Pheochromocytoma/paraganglioma; ENETS, European Neuroendocrine Tumor Society.
2.3. Clinicopathological Characteristics of the Tumor
Clinicopathological characteristics, such as primary tumor site and size, tumor stage, mitotic rate,
ki67 index, metastases, familiar history of MEN1, hormonal secretion, comorbidity, treatment and
follow-up, were collected for all patients.
Tumor size (mm) was defined as the maximum tumor diameter in the pathological specimen or
in the last computed tomography (CT) scan/magnetic resonance imaging (MRI) when the patient had
not undergone surgery or when the patient had multiple pancreatic nodules in case of MEN1. For
these patients, the diameter of the biggest pancreatic lesion was considered for the tumor size. Only in
a few cases (n = 3) was the tumor size not defined since the primary lesion had not been found. Tumor
stage at diagnosis was classified according to the ENETS criteria [20]. According to this, patients were
classified as those with localized disease (stage I–III) and patients with advanced disease (presence of
metastases, stage IV).
For the diagnosis of NET, immunohistochemistry for chromogranin A, synaptophysin and ki67
were performed for all formalin-fixed paraffin-embedded tissue sampl s deriving from biopsy or
surgery of the primary tumor and/or metastases [21]. Particularly, the evaluation of the mitotic
rate and ki67% index were performed as previously reported [22] according to ENETS criteria [20].
Additionally, according to WHO classification [18], all GEP-NETs were divided into well-differentiated
or poorly differentiated malignant neoplasms named neuroendocrine carcinomas (NECs). In this study,
only patients with well-differentiated/low grade GEP-NETs, graded as G1 (ki67% ≤2% and mitoses
<2) or G2 (ki67% 3–20% and mitoses 2–20) were include [18].
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At the time of the visit, disease status was defined as “disease free”, when there was no biochemical
and morphological evidence of the disease after tumor resection, “stable disease” or “progressive
disease” according to RECIST 1.1 criteria [23].
2.4. Lifestyle Habits
Lifestyle habits, including physical activity level and smoking habits, were investigated by a
standard questionnaire. Physical activity levels were expressed according to whether the participant
habitually engaged at least 30 min/day of aerobic exercise (YES/NO). Subjects were considered as
“current smokers” when they smoked at least one cigarette per day, “former smokers” when having
stopped smoking at least one year before the interview, and “non-current smokers”. Former and
non-current smoker were considered as “no-smoker” for the analyses.
2.5. Dietary Assessment
As widely reported previously [24–27], data were obtained during a face-to-face interview
between the patient and a qualified nutritionist. In detail, the dietary interview enabled the
quantification of food and drinks by using a photographic food atlas (≈1000 photographs) of known
portion sizes to ensure accurate completion of the records [28]. Dietary data, including beverage
intakes and alcohol consumption, were collected by 7-day food records that were evaluated by a
nutritionist. Data were stored and processed later, using a specific software (Terapia Alimentare
Dietosystem® DS-Medica, (http://www.dsmedica.info) that calculate daily caloric intake and the
quantities of macronutrients (animal and plant protein; total, complex and simple carbohydrates;
total fat, saturated fatty acid (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids
(PUFA): n-6 PUFA, n-3 PUFA).
2.6. Adherence to the Mediterranean Diet
As previously reported [17,24–26,29–32], the adherence to the MD was evaluated using the 14-item
questionnaire for the assessment of PREvención con DIeta MEDiterránea (PREDIMED) [33]. A qualified
nutritionist administered the questionnaire during a face-to-face interview to all the enrolled subjects.
Briefly, for each item scores 1 and 0 were assigned; the PREDIMED score was calculated as follows:
0–5, lowest adherence; score 6–9, average adherence; score ≥10, highest adherence [33].
2.7. Anthropometric Measurements and Blood Pressure
Anthropometric measurements were obtained with subjects wearing light clothes and without
shoes. BMI was calculated by weight and height (weight (kg) divided by height squared (m2), kg/m2).
Height was measured to the nearest 1 cm using a wall-mounted stadiometer (Seca 711; Seca, Hamburg,
Germany). Body weight was derived to the nearest 50 g using a calibrated balance beam scale (Seca
711; Seca, Hamburg, Germany). Subjects were classified by BMI according to WHO’s criteria as
normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2), grade I obesity (BMI
30.0–34.9 kg/m2), grade II obesity (BMI 35.0–39.9 kg/m2), grade III obesity (BMI ≥ 40.0 kg/m2) [34].
Waist Circumference (WC) was measured to the closest 0.1 cm at the natural indentation or at a midway
level between lower edge of the rib cage and iliac crest if no natural indentation was visible using a
non-stretchable measuring tape, in line with the National Center for Health Statistics (NCHS) [35].
In all individuals systolic (SBP) and diastolic (DBP) blood pressure were measured three times, every
two min after the subject had been sitting for at least 10 min, with a random sphygmomanometer
(Gelman Hawksley Ltd., Sussex, UK). The mean of the second and third reading was recorded.
2.8. Assay Methods
Samples were collected in the morning between 8 and 10 a.m., after an overnight fast of at least 8 h
and stored at −80 ◦C until being processed. All biochemical analyses including fasting plasma glucose,
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total cholesterol, fasting plasma triglycerides were performed with a Roche Modular Analytics System
in the Central Biochemistry Laboratory of our Institution. Low-density lipoprotein (LDL) cholesterol
and high-density lipoprotein (HDL) cholesterol were determined by a direct method (homogeneous
enzymatic assay for the direct quantitative determination of LDL and HDL cholesterol).
2.9. Bioelectrical Impedance Analysis
Bioelectrical impedance analysis was performed using a BIA phase-sensitive system by
experienced observers (an 800-µA current at a frequency single-frequency of 50 kHz BIA 101 RJL, Akern
Bioresearch, Florence—Italy) [36], as already amply reported in previous studies [17,29,37]. Based on
the European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines [38], all participants
were supine with limbs slightly spread apart from the body, had refrained from eating, drinking, and
exercising for six hours with no alcohol within 24 h before testing. Shoes and socks were removed
and contact areas were scrubbed with alcohol immediately before electrode placement. Electrodes
(BIATRODES Akern Srl; Florence—Italy) were placed on the dorsal surface of the right hand proximal
to the phalangeal–metacarpal joint and on the superior surface of the right foot distal to the transverse
arch. Sensor electrodes were placed on the right wrist at the midpoint between the distal prominence
of the radius and ulna, and on the right ankle between the medial and lateral malleoli, as described
by Kushner et al. [39]. All measurements were performed under strictly standardized conditions by
the author, using the same device in order to avoid interobserver and interdevice variability. The
instrument was routinely checked with resistors and capacitors of known values. Reliability for
within-day and between-day measurements by the same observer were <2.7% for resistance (R), <2.9%
for reactance (Xc), and <3.1% for R, <2.4% for Xc, respectively. The coefficient of variation (CV) of
repeated measurements of R and Xc at 50 kHz was assessed in 14 patients (7 males and 7 females) by
the same observer: CVs were 1.9% for R and 1.8% for Xc. The PhA was derived from conditions under
50 kHz according to the following formula: PhA (◦, degrees) = arctangent Xc/R ((Xc/R) × (180/pi)).
2.10. Statistical Analysis
The data distribution was evaluated by the Kolmogorov–Smirnov test and the abnormal data
were normalized by logarithm. All variables were logarithmically transformed and back-transformed
for presentation in tables and figures. The chi-square (χ2) test was used to determine the significance
of differences in the frequency distribution. Differences between GEP-NETs patients and the control
group were analyzed by Student’s paired t-test, while the differences among the several parameters
with the disease status were analyzed by Student’s unpaired t-test, followed by Bonferroni post hoc
analysis. p values < 0.05 were considered as statistically significant.
Proportional Odds Ratio (OR) models, p-value, 95% Interval Confidence (IC), and R2, were
performed to assess the association among quantitative variables (grading system and metastasis).
Multinomial logistic regression, χ2, p-value, and Akaike Information Criterion (AIC), were performed
to model the relationship between the several parameters with the three groups of disease status
(disease free, stable disease, and progressive disease). The correlations between the different variables
were performed using Pearson r correlation coefficients. Receiver operator characteristic (ROC) curve
analysis was performed to determine sensitivity and specificity, area under the curve (AUC), and IC,
as well as cut-off values for PhA and PREDIMED score in detecting Sartorius HS score above the
median values in the HS patients. Test AUC for ROC analysis was also performed. For α level the 0.05
type I error was selected and for β level the 0.20 type II error was selected. In these last analyses, only
variables with a p-value < 0.05 in the univariate analysis (partial correlation) were entered. Variables
with a variance inflation factor (VIF) >10 were excluded to avoid multicollinearity. Values ≤ 5%
were considered statistically significant. Data were analyzed using the MedCalc® package (Version
12.3.0 1993–2012 MedCalc Software bvba-MedCalc Software, Mariakerke, Belgium) and SPSS Software
(PASW Version 21.0, SPSS Inc., Chicago, IL, USA).
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3. Results
3.1. Patient Population
A total of 83 patients (F:M = 43:40), mean age 56.66 (18–80) years, affected by GEP-NET were
included in the study. Mean size of the tumor was 24.96 ± 23.79 mm. Primary NET were located in the
pancreas (n = 47, 56.6%), stomach (n = 12, 14.5%), small intestine (n = 14, 16.9%), appendix (n = 5, 6%),
colon (n = 2, 2.4%) and in a few cases the primary site was unknown (n = 3, 3.6%). The majority of
patients had non-functioning GEP-NET (n = 75, 90.4%). Among patients with pancreatic NET, 39 were
non-functioning (83%), 5 were insulinomas (10.6%), 2 were gastrinomas (4.2%) and 1 was VIPoma
(2.2%). All patients with functioning pancreatic NET underwent endoscopic surgery of the lesion at
least 6 months before the visit. Twenty two patients (26.5%) had a MEN1 syndrome.
According to the pathological parameters, the mitotic rate and ki67% index, all GEP-NET were
classified as well-differentiated tumor G1 (n = 48, 57.8%) or G2 (n = 35, 42.2%). At diagnosis, 22 patients
(26.5%) had metastases (stage IV), the majority of them in the liver. At the moment of the visit
considered for the study, 34 patients (41%) were disease free, 28 (33.7%) had stable disease and 21
(25.3%) had progressive disease according to the RECIST1.1 criteria.
3.2. Nutritional Status in GEP-NET Patients and Control Group
Clinical and anthropometric characteristics, lifestyle habits, blood pressure, metabolic profile, and
bioelectrical parameters deriving from BIA of GEP-NET patients compared to controls are shown in
Table 1. To note, GEP-NET patients smoked less (p = 0.005), presented higher blood pressure values
and a worse metabolic profile (p < 0.001), and had smaller PhA according to gender (p < 0.001) in
comparison to the control group (Table 1).
Table 1. Demographic, clinical, metabolic, and bioelectrical parameters of GEP-NET patients compared
to controls.
Parameters GEP-NET Patientsn. 83
Control Group
n. 83 p-Value
Clinical characteristics
Gender-male
Age-mean (range)
40 (48.2%)
56 (18–80)
40 (48.2%)
57 (23–82)
0.877 (χ2 = 0.02)
0.307
Lifestyle Habits
Smoking-yes
Physical activity-yes
32 (38.6%)
41 (49.4%)
51 (61.4%)
45 (54.2%)
0.005 (χ2 = 7.81)
0.986 (χ2 = 0.00)
Anthropometric measurement
BMI (kg/m2)
WC (cm)
27.79 ± 5.57
92.76 ± 15.38
27.54 ± 2.84
87.92 ± 10.66
0.859
0.050
Blood pressure
SBP (mmHg)
DBP (mmHg)
123.79 ± 12.16
76.99 ± 7.99
118.49 ± 11.93
73.86 ± 6.87
0.010
0.007
Metabolic profile
Fasting Glucose (mg/dL) 109.52 ± 16.51 89.29 ± 11.72 <0.001
Total cholesterol (mg/dL) 194.83 ± 41.19 149.08 ± 22.41 <0.001
HDL cholesterol (mg/dL) 44.43 ± 14.35 50.45 ± 8.67 <0.001
LDL cholesterol (mg/dL) 123.35 ± 40.85 77.20 ± 25.00 <0.001
Triglycerides (mg/dL) 135.23 ± 47.81 107.22 ± 26.57 <0.001
Bioelectrical variables
R (Ω) 514.23 ± 80.21 523.54 ± 59.99 0.279
Xc (Ω) 42.31 ± 9.50 52.19 ± 8.13 <0.001
PhA (◦) 4.73 ± 0.88 5.70 ± 0.55 <0.001
PhA (◦) males 4.69 ± 0.86 5.76 ± 0.60 <0.001
PhA (◦) females 4.76 ± 0.91 5.65 ± 0.52 <0.001
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: GEP-NET, Gastroenteropancreatic
Neuroendocrine Tumor; BMI, Body Mass Index; WC, Waist Circumference; SBP, Systolic Blood Pressure; DBP,
Diastolic Blood Pressure; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; R, Resistance; Xc,
Reactance; PhA, Phase angle.
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Data on Mediterranean food frequencies were analyzed by using the 7-day food records. Even
though no differences in energy intake were observed between the two groups, GEP-NET patients
consumed a lower quantity of plant protein (p = 0.003), complex carbohydrate (p < 0.001), MUFA
(p = 0.009) and n-3 PUFA (p < 0.001), and higher quantity of simple carbohydrate (p < 0.001) and n-6
PUFA (p < 0.001) than control subjects (Table S1).
Analyzing in details the frequency of the assumed dietary components included in the PREDIMED
questionnaire, GEP-NET patients consumed vegetables less frequently (p = 0.005), fruits (p = 0.001),
wine (p = 0.013), fish/seafood (p = 0.005), nuts (p < 0.001), and more frequently red/processed meats
(p = 0.017), butter, cream, margarine (p = 0.001) and soda drinks (p = 0.003); Table 2. Therefore, the
PREDIMED score was significantly lower in GEP-NET patients compared to control group (6.18 ± 2.25
vs. 7.39 ± 2.54; p = 0.001). The PREDIMED score was positively correlated with PhA both in males and
in females, in both GEP-NET patients (r = 0.724, p < 0.001 and r = 0.682, p < 0.001; respectively) and
control (r = 0.919, p < 0.001 and r = 0.859, p < 0.001; respectively).
Regarding the adherence to the MD, only 4.8% of GEP-NET patients vs 26.5% of controls presented
a high adherence to this dietary regimen (p = 0.001); Table 2.
Table 2. Response frequency of dietary components included in the PREDIMED questionnaire of the
GEP-NET patients and control group.
Questions of PREDIMED Questionnaire
GEP-NET
Patients
n. 83
Control
Group
n. 83
n % n % χ2 p-Values
Use of extra virgin olive oil as main culinary lipid 78 94.0 79 95.2 0.00 1.000
Extra virgin olive oil >4 tablespoons 49 59.0 52 62.7 0.10 0.751
Vegetables ≥2 servings/day 30 36.1 49 59.0 7.83 0.005
Fruits ≥3 servings/day 27 32.5 50 60.2 11.72 0.001
Red/processed meats <1/day 25 30.1 41 49.4 5.66 0.017
Butter, cream, margarine <1/day 63 75.9 40 48.2 12.38 0.001
Soda drinks <1/day 34 41.0 54 65.1 8.73 0.003
Wine glasses ≥7/week 14 16.9 29 34.9 6.15 0.013
Legumes ≥3/week 38 45.8 37 44.6 0.00 1.000
Fish/seafood ≥3/week 18 21.7 36 43.4 7.93 0.005
Commercial sweets and confectionery ≤2/week 43 51.8 39 47.0 0.22 0.641
Tree nuts ≥3/week 20 24.1 33 39.8 21.14 <0.001
Poultry more than red meats 41 49.4 43 51.8 0.02 0.876
Use of sofrito sauce ≥2/week 33 39.8 31 37.3 0.03 0.873
PREDIMED categories
Low adherence to the MD 30 36.1 28 33.7 0.03 0.870
Average adherence to the MD 49 59.0 33 39.8 5.42 0.019
High adherence to the MD 4 4.8 22 26.5 13.18 0.001
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: GEP-NET, Gastroenteropancreatic
Neuroendocrine Tumor; PREDIMED, PREvención con DIeta MEDiterránea; MD, Mediterranean Diet.
3.3. Nutritional Status in GEP-NET Patients According to Tumor Grading, Stage and Disease Status
Differences in age, anthropometric measurement, blood pressure, metabolic profile, bioelectrical
variables, and nutritional assessment in the GEP-NET patients grouped by grading G1/G2 and stage
are summarized in Table 3. Interestingly, patients with GEP-NET G2 and stage IV had significantly
higher levels of SBP, fasting glucose, total and LDL cholesterol, triglycerides, and lower levels of HDL
cholesterol as well as a lower PREDIMED score and PhA in comparison to patients with localized
GEP-NET G1 (Table 3).
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Table 3. Demographic, clinical, metabolic, and bioelectrical parameters in the GEP-NET patients
according to tumor grading and stage.
Parameters G1n. 48
G2
n. 35 p-Value
Stage I-III
(Localized
Disease)
n. 61
Stage IV
(Metastases)
n. 22
p-Value
Age (years) 54.85 ± 17.31 59.14 ± 12.64 0.103 55.72 ± 16.82 59.27 ± 11.37 0.123
Anthropometric measurement
BMI (kg/m2) 27.09 ± 5.89 28.74 ± 5.01 0.141 27.23 ± 5.77 29.31 ± 4.75 0.081
WC (cm) 90.29 ± 14.99 96.15 ± 15.46 0.092 90.72 ± 15.42 98.41 ± 14.05 0.032
Blood pressure
SBP (mmHg) 121.04 ± 11.39 127.57 ± 12.32 0.017 121.89 ± 12.08 129.09 ± 10.98 0.014
DBP (mmHg) 75.83 ± 7.88 78.57 ± 8.00 0.130 76.15 ± 7.27 79.32 ± 9.54 0.213
Metabolic profile
Fasting Glucose (mg/dL) 104.38 ± 15.61 116.57 ± 15.23 0.001 106.26 ± 16.32 118.54 ± 13.64 0.001
Total cholesterol (mg/dL) 177.54 ± 28.14 218.54 ± 44.67 <0.001 186.74 ± 37.16 217.27 ± 44.26 0.009
HDL cholesterol (mg/dL) 46.97 ± 11.77 40.94 ± 16.83 0.007 47.00 ± 13.94 37.31 ± 13.27 0.002
LDL cholesterol (mg/dL) 106.02 ± 27.74 147.13 ± 44.21 <0.001 114.99 ± 35.51 146.55 ± 46.31 0.013
Triglycerides (mg/dL) 122.73 ± 37.34 152.37 ± 55.33 0.050 123.75 ± 41.61 167.05 ± 50.36 0.003
Bioelectrical variables
R (Ω) 502.08 ± 75.14 530.89 ± 84.95 0.125 511.97 ± 79.39 520.50 ± 84.01 0.693
Xc (Ω) 45.89 ± 7.56 37.40 ± 9.78 <0.001 43.70 ± 8.09 38.45 ± 12.02 0.008
PhA (◦) 5.26 ± 0.62 4.00 ± 0.65 <0.001 4.93 ± 0.80 4.16 ± 0.86 <0.001
Nutritional assessment
PREDIMED score 7.56 ± 1.28 4.29 ± 1.87 <0.001 6.69 ± 2.05 4.77 ± 2.22 <0.001
Total energy (kcal) 2223.29 ± 235.67 2307.88 ± 235.47 0.107 2256.96 ± 231.39 2264.49 ± 260.66 0.943
Protein (g of total kcal) 94.59 ± 12.21 101.77 ± 16.08 0.026 96.21 ± 12.29 101.55 ± 18.66 0.191
Animal (g of total kcal) 70.31 ± 11.54 73.77 ± 10.25 0.129 71.68 ± 11.11 71.99 ± 11.26 0.903
Plant (g of total kcal) 24.29 ± 10.01 28.01 ± 14.32 0.236 24.52 ± 10.42 29.54 ± 15.51 0.178
Carbohydrate (g of total kcal) 300.19 ± 36.57 308.89 ± 34.06 0.246 304.80 ± 36.50 301.25 ± 33.58 0.706
Complex (g of total kcal) 188.41 ± 23.05 190.63 ± 22.83 0.633 190.53 ± 23.27 186.06 ± 21.80 0.431
Simple (g of total kcal) 111.78 ± 15.77 118.27 ± 14.01 0.040 114.27 ± 15.53 115.19 ± 15.02 0.785
Fat (gr of total kcal) 71.57 ± 7.60 73.91 ± 9.57 0.275 72.55 ± 7.66 72.59 ± 10.73 0.879
SFA (g of total kcal) 25.79 ± 5.16 26.80 ± 10.30 0.664 26.03 ± 6.55 26.72 ± 10.46 0.829
MUFA (g of total kcal) 30.94 ± 3.65 31.34 ± 3.50 0.587 31.12 ± 3.36 31.07 ± 4.19 0.877
PUFA (g of total kcal) 14.84 ± 3.94 15.77 ± 5.80 0.566 15.39 ± 5.34 14.79 ± 2.90 0.791
n-6 PUFA (g/day) 7.64 ± 3.58 8.83 ± 4.86 0.173 8.21 ± 4.65 7.96 ± 2.57 0.500
n-3 PUFA (g/day) 7.20 ± 1.59 6.94 ± 1.98 0.415 7.18 ± 1.67 6.83 ± 1.99 0.299
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: GEP-NET, Gastroenteropancreatic
Neuroendocrine Tumor; G, grading; BMI, Body Mass Index; WC, Waist Circumference; SBP, Systolic Blood Pressure;
DBP, Diastolic Blood Pressure; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; R, Resistance; Xc,
Reactance; PhA, Phase angle; PREDIMED, PREvención con DIeta MEDiterránea; SFA, Saturated Fatty Acids; MUFA,
MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids.
Similar results were observed also when these parameters were correlated with disease status.
GEP-NET patients with progressive disease showed a significantly worse metabolic profile, a smaller
PhA (p < 0.001), and a significantly lower PREDIMED score (p < 0.001) in comparison to patients who
were free of the disease or with stable disease (Table 4).
When classified GEP-NET patients based on tumor grade G1/G2, stage and disease status, the
majority of patients with aggressive disease (GEP-NET G2, stage IV and progressive disease) presented
a low adherence to the MD according to PREDIMED categories (Figure 2 and Table S2).
In details, 28 out 35 (80%) patients with G2 GEP-NET, 13 out 22 (59%) patients with metastases
and 15 out 21 (71.4%) patients with progressive disease had significantly lower adherence to the MD
(Figure 2). On the contrary, 87.5%, 65.5%, and 67.7% of patients with GEP-NET G1, localized disease
and free of disease, respectively, had an average adherence to the MD. Not one of the patients with
aggressive tumor had a high adherence to the MD according to PREDIMED categories (Figure 2). No
significant differences were observed when these patients were classified for gender, smoking and
physical activity (Table S2).
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Table 4. Demographic, clinical, metabolic and bioelectrical parameters in the GEP-NET patients
according to disease status.
Parameters
Disease Status
Free of the Disease
n. 34
Stable Disease
n. 28
Progressive Disease
n. 21 p-Value
Age (years) 55.61 ± 17.33 57.71 ± 15.23 56.95 ± 13.51 0.720
Anthropometric measurement
BMI (kg/m2) 27.21 ± 4.94 27.54 ± 6.72 29.06 ± 4.83 0.411
WC (cm) 90.93 ± 16.20 92.36 ± 14.44 96.26 ± 15.36 0.458
Blood pressure
SBP (mmHg) 123.08 ± 12.55 121.79 ± 11.07 127.62 ± 12.16 0.256
DBP (mmHg) 76.02 ± 7.66 77.14 ± 7.75 78.33 ± 8.99 0.631
Metabolic profile
Fasting Glucose (mg/dL) 105.38 ± 12.99 106.82 ± 16.87 119.81 ± 17.42 0.005
Total cholesterol (mg/dL) 195.67 ± 41.66 178.64 ± 32.72 215.05 ± 42.99 0.017
HDL cholesterol (mg/dL) 42.15 ± 13.94 49.18 ± 12.43 41.81 ± 14.35 0.035
LDL cholesterol (mg/dL) 126.23 ± 38.67 105.35 ± 33.54 142.70 ± 44.65 0.012
Triglycerides (mg/dL) 136.50 ± 41.33 120.57 ± 38.41 152.71 ± 62.74 0.327
Bioelectrical variables
R (Ω) 512.71 ± 83.84 507.61 ± 73.76 525.52 ± 85.06 0.767
Xc (Ω) 41.65 ± 9.88 45.79 ± 7.76 38.76 ± 9.84 0.025
PhA (◦) 4.66 ± 0.82 5.19 ± 0.71 4.22 ± 0.91 <0.001
Nutritional assessment
PREDIMED score 6.91 ± 2.25 6.54 ± 1.79 4.52 ± 2.02 <0.001
Total energy (kcal) 2256.94 ± 257.14 2254.24 ± 204.66 2268.51 ± 257.36 0.983
Protein (g of total kcal) 96.82 ± 13.50 97.39 ± 14.13 99.22 ± 16.36 0.855
Animal (g of total kcal) 71.87 ± 10.06 71.94 ± 10.98 71.37 ± 13.18 0.948
Plant (g of total kcal) 24.96 ± 10.62 25.44 ± 10.98 27.85 ± 15.63 0.752
Carbohydrate (g of total kcal) 302.62 ± 37.01 303.83 ± 30.79 305.91 ± 40.54 0.954
Complex (g of total kcal) 188.00 ± 23.11 189.85 ± 19.44 190.84 ± 27.26 0.902
Simple (g of total kcal) 114.61 ± 15.60 113.98 ± 14.46 115.07 ± 16.62 0.979
Fat (g of total kcal) 73.24 ± 9.49 72.15 ± 6.69 72.00 ± 9.31 0.868
SFA (g of total kcal) 27.26 ± 7.87 25.67 ± 5.12 25.24 ± 10.17 0.380
MUFA (g of total kcal) 30.88 ± 3.76 31.40 ± 3.22 31.10 ± 3.86 0.824
PUFA (g of total kcal) 15.10 ± 6.12 15.08 ± 2.96 15.65 ± 4.53 0.653
n-6 PUFA (gr/day) 7.99 ± 5.08 7.71 ± 2.77 8.97 ± 4.21 0.385
n-3 PUFA (gr/day) 7.11 ± 1.99 7.38 ± 1.03 6.68 ± 2.10 0.280
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: GEP-NET, Gastroenteropancreatic
Neuroendocrine Tumor; BMI, Body Mass Index; WC, Waist Circumference; SBP, Systolic Blood Pressure; DBP,
Diastolic Blood Pressure; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; R, Resistance; Xc,
Reactance; PhA, Phase angle; PREDIMED, PREvención con DIeta MEDiterránea; SFA, Saturated Fatty Acids; MUFA,
MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids.
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Figure 2. Adherence to the Mediterranean Diet according to PREDIMED categories in GEP-NET
patients classified by tumor grade G1/G2 (A), stage (B), and disease status (C). Abbreviation: GEP-NET,
Gastroenteropancreatic Neuroendocrine Tumor; PREDIMED, PREvención con DIeta MEDiterránea;
MD, Mediterranean Diet.
3.4. Correlation between Tumor Aggressiveness and Nutritional Status in GEP-NET Patients
Different markers, such as grading, stage, progressive disease, ki67% index, and tumor size, were
evaluated to investigate tumor aggressiveness.
Nutrients 2018, 10, 1854 11 of 18
To assess the association of grading and stage, a bivariate proportional OR model with age,
anthropometric measurement, blood pressure, metabolic profile, bioelectrical variables, and nutritional
assessment was performed (Table 5).
Table 5. Bivariate proportional odds ratio model performed to assess the association of tumor
aggressiveness with demographic, clinical, metabolic, and bioelectrical parameters.
Parameters
Grading G2 Stage IV (Metastases)
OR p-Value 95% CI R2 OR p-Value 95% CI R2
Age (years) 1.02 0.217 0.99–1.05 0.019 1.02 0.359 0.98–1.05 0.010
Anthropometric measurement
BMI (kg/m2) 1.06 0.191 0.97–1.15 0.021 1.07 0.145 0.98–1.17 0.026
WC (cm) 0.07 0.049 0.99–1.06 0.036 1.03 0.049 1.00– 1.07 0.048
Blood pressure
SBP (mmHg) 1.05 0.018 1.01–1.09 0.071 1.05 0.020 1.00–1.10 0.069
DBP (mmHg) 1.04 0.125 0.99–1.11 0.029 1.05 0.114 0.99–1.12 0.031
Metabolic profile
Fasting Glucose (mg/dL) 1.06 0.002 1.02–1.09 0.136 1.05 0.005 1.01–1.09 0.108
Total cholesterol (mg/dL) 1.03 <0.001 1.02–1.05 0.241 1.02 0.004 1.00–1.04 0.108
HDL cholesterol (mg/dL) 0.97 0.044 0.94–1.00 0.045 0.93 0.011 0.88–0.98 0.105
LDL cholesterol (mg/dL) 1.03 <0.001 1.02–1.05 0.242 1.02 0.003 1.00–1.04 0.114
Triglycerides (mg/dL) 1.01 0.007 1.00–1.03 0.094 1.02 0.001 1.00–1.04 0.157
Bioelectical variables
R (Ω) 1.00 0.109 0.99–1.01 0.032 1.00 0.667 0.99–1.00 0.002
Xc (Ω) 0.88 <0.001 0.83–0.95 0.200 0.94 0.031 0.89–0.99 0.060
PhA (◦) 0.01 <0.001 0.01–0.08 0.529 0.31 0.001 0.15–0.64 0.149
Nutritional assessment
PREDIMED score 0.31 <0.001 0.19–0.50 0.486 0.66 0.001 0.51–0.85 0.137
Total energy (kcal) 1.00 0.113 1.00–1.01 0.031 1.00 0.898 0.99–1.00 0.000
Protein (g of total kcal) 1.01 0.029 1.00–1.07 0.061 1.02 0.042 0.99–1.06 0.026
Animal (g of total kcal) 1.03 0.164 0.98–1.07 0.024 1.00 0.909 0.96–1.05 0.000
Plant (g of total kcal) 1.03 0.171 0.99–1.07 0.023 1.03 0.002 0.99–1.08 0.033
Carbohydrate (g of total kcal) 1.00 0.272 0.99–1.02 0.015 0.99 0.686 0.98–1.01 0.002
Complex (g of total kcal) 1.00 0.661 0.98–1.02 0.002 0.99 0.430 0.97–1.01 0.008
Simple (g of total kcal) 1.03 0.042 0.99–1.06 0.044 1.00 0.808 0.97–1.04 0.001
Fat (gr of total kcal) 1.03 0.218 0.98–1.09 0.019 1.00 0.983 0.95–1.06 0.000
SFA (g of total kcal) 1.02 0.555 0.96–1.08 0.004 1.01 0.136 0.95–1.08 0.002
MUFA (g of total kcal) 1.03 0.610 0.91–1.17 0.003 0.99 0.954 0.87–1.14 0.000
PUFA (g of total kcal) 1.04 0.391 0.95–1.14 0.009 0.97 0.614 0.87–1.09 0.003
n-6 PUFA (g/day) 1.07 0.081 0.96–1.20 0.020 0.99 0.807 0.87–1.11 0.001
n-3 PUFA (g/day) 0.92 0.502 0.71–1.18 0.005 0.89 0.428 0.68–1.18 0.008
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: BMI, Body Mass Index; WC, Waist
Circumference; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL, High-Density Lipoprotein; LDL,
Low-Density Lipoprotein; R, Resistance; Xc, Reactance; PhA, Phase angle; PREDIMED, PREvención con DIeta
MEDiterránea; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty
Acids; OR, Odds Ratio; IC, Interval Confidence.
Metastatic G2 tumor were significantly associated with higher values of WC (p = 0.049 for both),
SBP (p = 0.018 and p = 0.020 for G2 and stage IV, respectively), metabolic profile (p < 0.001 for total
and LDL cholesterol, p = 0.002 and p = 0.007 for fasting glucose and triglycerides, respectively, and G2;
p = 0.004, p = 0.003, p = 0.005 and p = 0.001 for total cholesterol, LDL cholesterol, fasting glucose and
triglycerides, respectively, and stage IV), protein consumption (p = 0.029 and p = 0.042 for G2 and stage
IV, respectively), and with lower levels of HDL cholesterol (p = 0.044 and p = 0.011 for G2 and stage IV,
respectively), lower PhA (p < 0.001 and p = 0.001 for G2 and stage IV, respectively) and PREDIMED
score (p < 0.001 and p = 0.001 for G2 and stage IV, respectively; Table 5). In addition, GEP-NETs G2
were associated with higher consumption of simple carbohydrate (p = 0.042) and metastasized disease
with lower consumption of plant protein (p = 0.002).
A multinomial logistic regression model to assess the association between patients with
progressive disease and age, anthropometric measurement, blood pressure, metabolic profile,
bioelectrical variables, and nutritional assessment was performed (Table 6). Progressive disease
was associated with higher value of WC (p = 0.033), blood pressure (p = 0.05 and p = 0.027 for SBP and
DBP, respectively), fasting glucose (p = 0.043), triglycerides (p = 0.030), and lower HDL cholesterol
(p = 0.011), PhA (p = 0.010), and PREDIMED score (p = 0.005).
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Table 6. Multinomial logistic regression model to assess the association between disease status
with age, anthropometric measurement, blood pressure, metabolic profile, bioelectrical variables
and nutritional assessment.
Progressive Disease
Parameters χ2 p Value AIC
Age (years) 107.35 0.054 201.30
Anthropometric measurement
BMI (kg/m2) 176.49 0.125 317.39
WC (cm) 156.71 0.033 266.41
Blood pressure
SBD (mmHg) 28.64 0.050 75.82
DBD (mmHg) 23.06 0.027 56.61
Metabolic profile
Fasting Glucose (mg/dL) 116.57 0.043 215.48
Total cholesterol (mg/dL) 140.08 0.220 277.92
HDL cholesterol (mg/dL) 109.25 0.011 187.09
LDL cholesterol (mg/dL) 168.17 0.147 309.55
Triglycerides (mg/dL) 159.85 0.030 269.70
Bioelectical variables
R (Ω) 156.03 0.233 303.33
Xc (Ω) 82.00 0.088 173.49
PhA (◦) 85.71 0.010 154.83
Nutritional assessment
PREDIMED score 32.24 0.005 70.80
Total energy (kcal) 173.72 0.217 326.77
Protein (g of total kcal) 179.26 0.196 332.00
Animal (g of total kcal) 179.23 0.195 332.01
Plant (g of total kcal) 179.25 0.197 331.09
Carbohydrate (g of total kcal) 178.25 0.196 332.08
Complex (g of total kcal) 179.26 0.199 332.00
Simple (g of total kcal) 176.26 0.191 331.00
Fat (g of total kcal) 173.72 0.217 326.77
SFA (g of total kcal) 176.48 0.206 329.38
MUFA (g of total kcal) 173.72 0.217 326.77
PUFA (g of total kcal) 176.49 0.176 325.39
n-6 PUFA (gr/day) 176.50 0.206 329.39
n-3 PUFA (gr/day) 176.48 0.085 309.38
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: BMI, Body Mass Index; WC,
Waist Circumference; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL, High-Density Lipoprotein;
LDL, Low-Density Lipoprotein; R, Resistance; Xc, Reactance; PhA, Phase angle; PREDIMED, PREvención con
DIeta MEDiterránea; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated
Fatty Acids.
Correlations among ki67% index and tumor size with age, anthropometric measurement, blood
pressure, metabolic profile, bioelectrical variables and nutritional assessment, are summarized in
Table S3. ki67% showed significant correlations with all anthropometric measurements (p = 0.002 for
BMI and p < 0.001 for WC), metabolic profile (p < 0.001), SBP (p = 0.003), PhA and PREDIMED score
(p < 0.001). Tumor size correlated with SBP (p = 0.040), HDL cholesterol (p = 0.018), PhA (p = 0.001),
PREDIMED score (p < 0.001), and protein consumption (p = 0.036). After adjusting for BMI and WC,
all correlations for both ki67% and tumor size were maintained, except those with SBP (Table S3).
Three multiple linear regression analysis models including variables statistically correlated with
each oncological category (grading, tumor stage, and disease status) were performed to compare the
relative predictive power of the evaluated variables (Table 7).
Model 1 compared the relative predictive power of grading G1/G2 on WC, SBP, fasting glucose,
total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, PhA, PREDIMED score, protein, and
simple carbohydrate consumption. Using this model the PREDIMED score entered at the first step
(p < 0.001), followed by PhA (p < 0.001), and simple carbohydrate (p = 0.005). Model 2 compared the
relative predictive power of metastases (stage IV) on WC, SBP, DBP, fasting glucose, HDL cholesterol,
triglycerides, PhA, and PREDIMED score. Using this model, triglycerides entered at the first step
(p < 0.001), followed by the PREDIMED score (p = 0.003). In the model 3, the disease status was better
predicted by PREDIMED score (p < 0.001) (Table 7).
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Table 7. Multiple regression analysis models (stepwise method) with tumor aggressiveness and
nutritional parameters.
Parameters Multiple Regression Analysis
Model 1–Tumor Grading- R2 β t p value
PREDIMED score 0.591 −0.724 −9.45 <0.001
PhA (◦) 0.595 −0.394 −4.04 <0.001
Simple carbohydrate (g of total kcal) 0.629 0.194 2.88 0.005
LDL cholesterol (mg/dL) 0.646 0.171 2.19 0.031
Variable excluded: WC, SBP, fasting Glucose, total cholesterol, HDL cholesterol, triglycerides, Xc, protein (g of total kcal).
Model 2–Tumor Stage- R2 β t p value
Triglycerides (mg/dL) 0.151 0.402 3.95 <0.001
PREDIMED score 0.232 −0.306 −3.08 0.003
Variable excluded: WC, SBP, DBP, fasting Glucose, HDL cholesterol, PhA.
Model 3–Disease Status- R2 β t p value
PREDIMED score 0.152 −0.403 −3.96 <0.001
Variable excluded: WC, SBP, DBP, fasting Glucose, HDL cholesterol, triglycerides, PhA.
A p value in bold type denotes a significant difference (p < 0.05). Abbreviation: PREDIMED, PREvención con DIeta
MEDiterránea; PhA, Phase angle; LDL, Low-Density Lipoprotein; WC, Waist Circumference; SBP, Systolic Blood
Pressure; HDL, High-Density Lipoprotein; Xc, Reactance; DBP, Diastolic Blood Pressure.
The multiple linear regression analysis models including variables statistically correlating with
ki67% index and tumor size, were reported in Table S4. In the model 1, ki67% index was better
predicted by PhA (p < 0.001); in model 2 the dimension of lesion was better predicted by PREDIMED
score (p < 0.001) (Table S4).
ROC analysis was performed to determine the cut off values of the PREDIMED score and PhA
predictive of high grading, metastases, and disease status. A PREDIMED score ≤ 5 (p < 0.001,
sensitivity 80%, specificity 95.8%; Figure 3A) and a PhA ≤ 4.7◦ (p < 0.001, sensitivity 94.3%, specificity
81.2%, Figure 3B), could serve as thresholds for significant increased risk of G2 tumor.
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and PhA (B) predictive for the evaluation of increased risk of grading G2. Abbreviation: PREDIMED,
PREvención con DIeta MEDiterránea; PhA, phase angle; ROC, Receiver operator characteristic.
A PREDIMED score ≤4 could serve as a threshold for significantly increased risk of metastases
(p < 0.001, sensitivity 54.5%, specificity 82%; Figure 4A). A PREDIMED score ≤5 was associated
with a significant increased risk of progressive disease during follow-up (p < 0.001, sensitivity 71.4%,
specificity 75.8%; Figure 4B).
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4. Discussion
GEP-NET patients have been reported to have an impaired nutritional status (the metabolic
state, the dietary pattern and body composition), mostly due to excessive secretion of gastrointestinal
hormones and peptides, medical treatment, and surgical procedures [4,40]. Different studies have
shown that a poor nutritional status negatively impacts the clinical outcome of patients with NET [6,8,9].
Moreover, metabolic profile has been reported to worsen the severity of non-functioning GEP-NETs
being associated to a higher ki67% index and larger tumor size [5]. It has been suggested that nutritional
factors, such as the adherence to the MD, could influence the aggressiveness of different tumor types,
such as prostate, bladder and breast cancer [12–14], and that a low adherence to the MD pattern could
correlate with an increased risk of metabolic syndrome [16].
In our study we reported the difference of nutritional status, evaluated by BIA and its derived
parameter PhA, and dietary pattern between a selected group of GEP-NET patients and healthy control.
Moreover, in GEP-NET patients we observed a significant correlation among the nutritional status the
adherence to the MD and clinicopathological characteristics, including tumor grade, stage, disease
status, ki67% index, and tumor size.
In comparison to healthy controls, patients affected by GEP-NET had a dietary pattern
characterized by a significantly lower adherence to the MD, as assessed by PREDIMED score,
consuming less frequently vegetables, fruits, wine, fish/seafood, nuts, and more frequently
red/processed meats, butter, cream, margarine, and soda drinks. Moreover, in line with the
tumor-preventive potential effect of some food containing specific bioactive compounds (e.g., n-3
PUFA, or MUFA) [41], we observed that GEP-NET patients in comparison to healthy controls, had
a lower consumption of unsaturated fat that is beneficial for health, were associated with a lower
consumption of plant protein and complex carbohydrates and had a preferential consumption of
simple carbohydrate and n-6 PUFA. As already reported [16], we observed that GEP-NET patients
presented a worse metabolic profile probably as a consequence of a low adherence to the MD. Indeed,
the metabolic profile of these patients was characterized by an increase of waist circumference, higher
blood pressure values, and significantly higher blood levels of fasting glucose, total and LDL cholesterol
and triglycerides, and significantly lower levels of HDL cholesterol, all parameters that are associated
with a higher risk of metabolic syndrome. Thus, we confirmed that the worse metabolic parameters
correlated with higher ki67% index, as previously reported by our group [5]. However, we did not find
significant correlations between these parameters and larger tumor size, except for HDL cholesterol.
These contrasting results with our previous study [5] could be due to the fact that in the present study
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we did not consider the metabolic syndrome per se, but we focused our attention on the nutritional
status and dietary pattern.
We observed that GEP-NET patients presented a decreased PhA value in comparison to healthy
controls, as already reported in other diseases, such as infection disease, inflammation status, and
several cancer types [11]. It has been suggested that the PhA value correlated with disease severity [11]
and that a low value could be predictive of impaired prognosis (mortality, disease progression,
postoperative complications) in different tumors, such as pancreatic [42], breast [43], lung [44], and
colorectal cancer [45]. Moreover, we recently observed that PhA value correlated with the adherence
to MD independently of confounding factors [17]. In parallel with these findings, we demonstrated
that a decreased PhA, together with a lower adherence to the MD as assessed by a low PREDIMED
score, were the major predictors of GEP-NET aggressiveness. The ROC analysis showed that tumor
grading G2 was well predicted by a PREDIMED score ≤ 5 and a PhA value ≤ 4.7◦ with a sensitivity of
80% and 94.3% and a specificity of 95.8% and 81.2%, respectively. Thus, we concluded that a lower
adherence to the MD, together with a decreased PhA value and a consequent worse metabolic profile,
were associated with an increased GEP-NET aggressiveness, characterized by tumor grading G2, stage
IV and progressive disease, also after adjustments for gender, smoking, and physical activity.
However, there are some limits of this study that should be considered. The cross-sectional nature
of the study did not allow any causal association to be identified between MD or PhA and GEP-NETs
and to clearly determine the prognostic value of the adherence to the MD or of PhA for predicting its
clinical severity. Moreover, the suggested cut-off value of the PREDIMED score and PhAs to identify
tumor aggressiveness should be viewed with caution until results in larger populations become
available to perform an appropriate cross-validation. In addition, expert nutritionists are required for
the assessment, execution, and interpretation of BIA measurements, such as PhA. The main strength of
this study was the use of the 7-day food records. This method is the “gold standard” in validation
studies of different self-administered food frequency questionnaires and allows a more accurate
measurement of the dietary and macronutrient intakes compared to other questionnaires [46,47].
In order to improve the power of the study, we increased the homogeneity of the cohort of studied
patients by including non-functioning treatment-naïve patients or patients who underwent curative
surgery and who were biochemically free of disease for more than 6 months and who had not partaken
of medical treatment. Moreover, all patients had a diagnosis of well-differentiated G1/G2 GEP-NET
and both GEP-NET patients and matched controls were well characterized.
5. Conclusions
In conclusion, to the best of our knowledge, this is the first study to show a novel association
between nutritional status and aggressiveness of GEP-NETs in a selected cohort of adult patients. This
association potentially extends the benefit of adherence to the MD to GEP-NET patients and suggests
that BIA and PhA value may be used as tools for the nutritional management of these patients and as
markers of tumor aggressiveness. Moreover, this is the first study to indicate a dietary pattern that may
be beneficial for GEP-NET patients and that may modulate the risk of tumor aggressiveness, offering a
practical strategy for the management of these patients. Therefore, the assessment of nutritional status
should be recommended as good clinical practice in the evaluation of GEP-NET patients, in order to
identify high-risk subjects with a more aggressive tumor who could better benefit from a nutritional
intervention promoting the Mediterranean food pattern. Thus, a skilled nutritionist should be part of
the multidisciplinary health care team in NETs management, adapting the specific nutritional needs
to the course of the disease. Future well-designed dietary intervention trials on larger population
samples are needed to define specific dietary guidelines for NETs and elucidate the beneficial effects of
the MD on the survival outcomes of GEP-NET patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/12/1854/
s1, Table S1: Total energy and daily macronutrients/micronutrients intake of GEP-NET patients and control
group, Table S2: Grading, disease stage and disease status in GEP-NET patients according to gender, gender,
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with demographic, clinical, metabolic and bioelectrical parameters, Table S4: Multiple regression analysis models
(stepwise method) with the tumor aggressiveness and nutritional parameters.
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